70 assets in Myeloproliferative Neoplasm

Therapeutic assets addressing Myeloproliferative Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Retinol Myeloproliferative Neoplasm	St. Petersburg State Pavlov Medical University	P2	CCC (53)
Itacitinib Myeloproliferative Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (51)
Edetate Calcium Disodium Myeloproliferative Neoplasm	M.D. Anderson Cancer Center	P1/2	CCC (50)
Imgn632 Myeloproliferative Neoplasm	Fred Hutchinson Cancer Center	P1/2	CCC (50)
Vedolizumab Myeloproliferative Neoplasm	City of Hope Medical Center	P2	CCC (50)
Pacritinib Myeloproliferative Neoplasm	University of Washington	P2	CC (46)
Cytokine-Treated Veto Cells Myeloproliferative Neoplasm	M.D. Anderson Cancer Center	P1/2	CC (45)
Pevonedistat Myeloproliferative Neoplasm	M.D. Anderson Cancer Center	P1/2	CC (45)
Ipilimumab Myeloproliferative Neoplasm	OHSU Knight Cancer Institute	P1	CC (44)
Plerixafor Myeloproliferative Neoplasm	Stanford University	P1	CC (43)
Vactosertib Myeloproliferative Neoplasm	David Wald	P1	CC (43)
Vic-1911 Myeloproliferative Neoplasm	Masonic Cancer Center, University of Minnesota	P1/2	CC (43)
Zoledronate Myeloproliferative Neoplasm	University of Wisconsin, Madison	P1	CC (43)
Ciml-Nk Cells Myeloproliferative Neoplasm	Dana-Farber Cancer Institute	P1	CC (41)
Cytokine Induced Memory-Like Natural Killer Cells Myeloproliferative Neoplasm	Dana-Farber Cancer Institute	P1	CC (41)
Navitoclax Myeloproliferative Neoplasm	Jacqueline Garcia, MD	P1	CC (41)
PRT1419 Myeloproliferative Neoplasm	Prelude Therapeutics	P1	CC (41)
Recombinant Human Granulocyte Colony-Stimulating Factor Myeloproliferative Neoplasm	City of Hope Medical Center	P1	CC (41)
Succimer Myeloproliferative Neoplasm	M.D. Anderson Cancer Center	P1	CC (41)
LY 3410738 Myeloproliferative Neoplasm	Eli Lilly and Company	P1	NR ()

Showing 51 to 70 of 70 assets

PreviousPage 2 of 2Next